|
Post by David Grey on Nov 30, 2017 14:37:26 GMT -5
I spoke to Celerion - that study is NO longer recruiting - it did end a couple of months ago. I asked them to keep us in mind when another good program comes out.
|
|
|
Post by David Grey on Nov 30, 2017 13:53:57 GMT -5
I will reach out to them directly and see if we can get an update for you. I thought it ended a couple of months ago but will find out for sure.
|
|
|
Post by David Grey on Nov 30, 2017 12:29:27 GMT -5
call 410.706.8833 Healthy Men and Women Needed Pharmaron, located in downtown Baltimore is currently seeking volunteers to participate in a clinical research study to evaluate an investigational drug. We are looking for healthy men and women, non-smokers, ages 18 to 60, to participate in a study consisting of up to 13-26 days in house with 4 outpatient visits and 3 follow up phone calls. Qualified participants will be compensated for their time and effort. Contact our recruiting department now at 410.706.8833 or 1.866.706.8833 or email baltimore.recruiter@pharmaron-us.com Visit our website at www.pharmaron.com
|
|
|
Post by David Grey on Nov 30, 2017 12:09:30 GMT -5
Call 844-246-8459
The study includes a screening visit, In-house period of 15 days/ 14 overnight stay 1 outpatient visit and 1 end of the study. You may be compensated for your time and travel up to $3,500 for participating in the study. You must be: Healthy male between 18 – 55 years old with a BMI between 18 and 30. Females of non-child bearing potential that is surgically sterile or post- menopausal. Non-smoker or smokes less than 10 cigarettes per day.
Call 844 246- 8459
|
|
|
Post by David Grey on Nov 30, 2017 10:38:19 GMT -5
Healthy, non-smoking and age 18-55? Available for a 5-night stay and 1 follow-up? Study #5222. Up to $1,700. Call PRA: 913-370-9908.
|
|
|
Post by David Grey on Nov 28, 2017 15:12:35 GMT -5
Site Name Location Stipend Health Condition PAREXEL Baltimore, MD $2,240 to $2,240 Psoriasis and Psoriatic Diss, Skin Infections/Diss, Eczema (Atopic Dermatitis), Psoriatic Arthritis PAREXEL Baltimore, MD $6,220 to $6,220 *Healthy Volunteers Studies PAREXEL Baltimore, MD $3,425 to $3,425 *Healthy Volunteers Studies PAREXEL Baltimore, MD $2,240 to $2,240 Psoriasis and Psoriatic Diss, Psoriatic Arthritis PAREXEL Baltimore, MD $20 to $20 *Healthy Volunteers Studies PAREXEL Baltimore, MD $2,240 to $2,240 Psoriasis and Psoriatic Diss, Skin Infections/Diss, Skin Wounds, Eczema (Atopic Dermatitis), Hand Dermatitis, Psoriatic Arthritis, Ischemic Foot Ulcers, Atopic Dermatitis, Dermatitis, Atopic PAREXEL Baltimore, MD $4,575 to $4,575 *Healthy Volunteers Studies PAREXEL Baltimore, MD $4,000 to $4,000 *Healthy Volunteers Studies PAREXEL Baltimore, MD $3,250 to $3,250 *Healthy Volunteers Studies PAREXEL Baltimore, MD $4,000 to $4,000 *Healthy Volunteers Studies PAREXEL Baltimore, MD $20 to $5,870 Diet and Nutrition, *Healthy Volunteers Studies PAREXEL Glendale, CA $0 to $6,750 Parkinson's Disease PAREXEL Glendale, CA $0 to $8,185 *Healthy Volunteers Studies Parexel Glendale, CA $0 to $5,585 *Healthy Volunteers Studies to link to website and get phone number : www.studyscavenger.com/ClinicID/21/PAREXEL_MD
|
|
|
Post by David Grey on Nov 27, 2017 12:09:47 GMT -5
AGE 50-75? COVANCE HAS AN OPPORTUNITY FOR YOU! call 1-866-429-3700 Currently Recruiting for Clinical Research Study 8349-477 Requirements Include: - Healthy Men & Women , Age 50-75 - Compensation up to $7,412 will be provided for time & participation - 4 Consecutive Overnights & 9 Outpatient Visits - Located in Madison, WI Go to www.covanceclinicaltrials.com/en-us/study-details.html?caseStudyId=twtbstudy_794220210 or call 1-866-429-3700 3402 Kinsman Blvd. Madison, WI 53704
|
|
|
Post by David Grey on Nov 23, 2017 12:30:03 GMT -5
Study 172013-14: Men and women between 39 and 80 years old needed in Miami. Volunteers must be non-smokers. The study requires one stay of 5 nights at the clinic and no return visit. Inventiv Miami FL For all the details visit our website: inventivhealthmiami.com/studies/ Receive up to $1,415! Call us now at 1-844-441-0444.
|
|
|
Post by David Grey on Nov 23, 2017 5:58:32 GMT -5
|
|
|
Post by David Grey on Nov 21, 2017 12:53:50 GMT -5
This study is being done to test an investigational drug to treat eosinophilic esophagitis (which affects the lining of the esophagus). The study drug will be administered intravenously or by subcutaneous injection.
8307 Gault Lane San Antonio, TX 78209
(210) 225-5437
Sponsored By: ICON Early Phase Service Stipend: $3800 - $3800 Length of Study: 20 weeks Research Facility: Out-Patient Gender: Both Age: 1 - 55 Health Condition: *Healthy Volunteers Studies More Information: Vital signs, ECGs, physical examinations and pregnancy, drug and alcohol screens will be performed. Blood and urine samples will also be obtained during this study.
Participants will complete:
1 screening visit 5 consecutive overnights 8 outpatient visits To determine if you fully qualify, it will be necessary to obtain blood samples after a 10- hour fast. You have the option of fasting for the screening appointment, or, you may return at a later date. You may need to provide medical records to participate in this study. For more information, see below.
Qualified participants may be compensated up to $3,800 for time and travel.
If you are able to answer “YES” to the following statements, you may qualify for this study.
I am a healthy adult, meaning no significant medical conditions
I am between 18 and 55 years old
My BMI is between ≥ 18.0 and ≤ 30.0 kg/m2 and I weigh at least 88 lbs.
I am a non-smoker. I agree not to smoke for the duration of the study and to abide by the rules of the clinic, which is a non-smoking facility.
I have not received any investigational drug within 30 days prior to screening
If Female, I am not pregnant or breastfeeding
If Female and capable of becoming pregnant, I agree to use a highly effective od of contraception throughout the study and for 5 months after last dose. Acceptable ods of birth control in this study are: combined hormonal (estrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable or implantable placement of an intrauterine device or intrauterine hormone-releasing system bilateral tubal occlusion vasectomised partner sexual abstinence.
If Female and not capable of becoming pregnant, I am postmenopausal (for at least 2 years) or I am surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy at least 6 months before screening). Please bring medical records to screening.
If Male, I agree to use a latex condom during sexual contact with women of child-bearing potential (WOCBP) while participating in the study until 5 months after last dose
If Male, I agree to refrain from donating sperm during the study until 5 months after last dose
All subjects: Periodic abstinence (calendar, symptothermal, postovulation ods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea od are not acceptable ods of contraception. Female condom and male condom should not be used together.
I am willing to refrain from all alcohol consumption for 48 hours prior to Day 1, during confinement to the CRU, and to limit the intake of alcohol to no more than 2 units per day throughout the study. One unit of alcohol is defined as 8 g (10 mL) of absolute alcohol. This is the appmate amount in a 1/2 pint (300 mL) of beer, a single measure of spirit (25 mL), or a single glass of wine (100 mL).
I am able to communicate effectively in English with the study personnel
I do not have a history of any clinically important cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease
I do not have a history of cancer or lymphoproliferative disease within 10 years of screening (other than a successfully treated non‑metastatic cutaneous squamous cell or basal cell carcinoma, or adequately treated cervical carcinoma in situ)
I do not have a history of infection within 30 days of dosing on Day 1
I have not had systemic or diarrheal illness following travel or residence in endemic areas of parasitic/helminthic infections, history of clinical schistosomiasis, and a history of travel to endemic areas within preceding 6 months
I do not have a history of alcohol or drug abuse, or addiction, within 6 months prior to screening
I do not have a history of tuberculosis, listeriosis, or untreated parasitic infections
I have not received any drug by injection within 30 days of Day 1
I agree to abstain from strenuous physical activities for at least 24 hours prior to dosing (Day 1) and throughout the study
I do not have tattoos or other skin markings (e.g., scarring) that would prevent visualization (abdomen or the IV infusion area) of potential rashes due to study treatment. (NOTE: If you have more than 25% of your body tattooed you may be disqualified.)
I have not donated blood within 60 days prior to Day 1 and I agree not to donate blood while on study
I do not have a history of any severe or life-threatening allergic reactions to any drug, biologic, food, vaccine or latex
I tolerate oral medication well
I have not had problems having blood drawn in either arm, venous access or finger pricks.
It is important to understand that even if you feel that you meet all the above criteria, you are still required to complete the protocol screening procedures. Frequently, subjects do not qualify because of medical history or minor changes in vital signs, ECG and lab tests. Scheduling a screening appointment does not guarantee that you will qualify for that study. Additionally, subjects are screened on a first come-first served basis and studies may complete enrollment prior to your visit. Additionally, no guarantees can be made regarding group assignments for any particular study. ICON will not assume any liability for lost time, travel or failure to qualify.
|
|
|
Post by David Grey on Nov 21, 2017 12:20:12 GMT -5
ICON Early Phase Services is conducting a research study for healthy adults ages 18-55. This study is being done to test an investigational drug for the treatment of polycystic kidney disease. The study drug will be administered by subcutaneous injection. 8307 Gault Lane San Antonio, TX 78209 (210) 225-5437 Sponsored By: ICON Early Phase Service Stipend: $3300 - $3300 Length of Study: 2 weeks Research Facility: Out-Patient Gender: Both Age: 18 - 55 Health Condition: *Healthy Volunteers Studies More Information: Vital signs, ECGs, physical examinations and pregnancy, drug and alcohol screens will be performed. Blood and urine samples will also be obtained during this study. Participants will complete: 1 screening visit 3 consecutive overnights 10 outpatient visits To determine if you fully qualify, it will be necessary to obtain blood samples after a 10- hour fast[f1] . You have the option of fasting for the screening appointment, or, you may return at a later date. You may need to provide medical records to participate in this study. For more information, see below. Qualified participants may be compensated up to $3,300 for time and travel. If you are able to answer “YES” to the following statements, you may qualify for this study. I am a healthy adult, meaning no significant medical conditions I am between 18 and 55 years old My BMI is between ≥ 18.0 and ≤ 32.0 kg/m2 and I weigh between 99 lbs. and 220 lbs. inclusive I am a non-smoker and I have not used any tobacco or nie-containing products within 3 months prior to dosing. I agree not to smoke for the duration of the study and to abide by the rules of the clinic, which is a non-smoking facility. I have not participated in another clinical trial and/or been exposed to any investigational drug or device, or approved therapy for investigational use, within 28 days of first dose If Female, I am not capable of becoming pregnant and I have been postmenopausal for at least 12 months or I am surgically sterile (ovaries removed, uterus removed) or I have medically confirmed ovarian failure. Please bring documentation to screening if possible. If Male, I agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond dosing of study drug. (NOTE: No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non‑vasectomized male. If Male, I agree not to donate sperm from dosing until 90 days after receiving last dose If Male, I am not planning a pregnancy with my partner within 90 days after dosing of study drug I am able to communicate effectively in English with the study personnel I do not have tattoos or scarring on or near the abdominal site of the subcutaneous injection I do not have a history of any malignancy, including any cancer, with the exception of local cervical cancer (treated with hysterectomy) and successfully treated skin cancers such as squamous or basal cell carcinoma I do not have a history or presence of an infection caused by bacteria, viruses, fungi, or protozoa I do not have a history or presence of any clinically significant local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening I have not had fever, or a viral or bacterial infection within 14 days prior to screening, at screening, at Day -1 check-in, or at Day 1 dosing I have not had treatment with any monoclonal antibody within 3 months prior to dosing I do not have a history or presence of alcohol or drug abusewithin the past 2 years prior to screening I am able to refrain from using any drug, including prescription and non‑prescription medications and herbal remedies, from 14 days prior to dosing until completion of end‑of‑study procedures. (NOTE: (up to 2 g per 24‑hour period) may be permitted during the study.) I have not been on a specialized or restrictive diet (vegan, vegetarian, gluten-free, etc.) within the 28 days prior to dosing and throughout the study I have not donated blood, or had significant blood loss, within 56 days prior to dosing I have not donated plasma within 7 days prior to dosing I have not had any major surgical procedure within 3 months prior to dosing (NOTE: Excluding minor cosmetic surgery or minor dental procedures.) I tolerate oral medication well I have not had problems having blood drawn in either arm, venous access or finger pricks. It is important to understand that even if you feel that you meet all the above criteria, you are still required to complete the protocol screening procedures. Frequently, subjects do not qualify because of medical history or minor changes in vital signs, ECG and lab tests. Scheduling a screening appointment does not guarantee that you will qualify for that study. Additionally, subjects are screened on a first come-first served basis and studies may complete enrollment prior to your visit. Additionally, no guarantees can be made regarding group assignments for any particular study. ICON will not assume any liability for lost time, travel or failure to qualify. To determine if you fully qualify, it will be necessary to obtain blood and urine samples after a 10-hour fast. You have the option of fasting for a blood or urine sample at the screening appointment, or, you may return at a later date for us to obtain these samples to view full study details or go to ICON's website : www.studyscavenger.com/SiteID/4fa72512-b765-4d86-a69d-d714c32c91e6/healthy-re-3877-0004
|
|
|
Post by David Grey on Nov 21, 2017 12:14:22 GMT -5
|
|
|
Post by David Grey on Nov 19, 2017 10:02:52 GMT -5
ICON Early Phase Services is conducting a research study for adults with celiac disease within the age range of 18-65. This study is being done to test the dosing level of an investigational drug for the treatment of celiac disease. The study drug will be administered by IV infusion.
8307 Gault Lane San Antonio, TX 78209
(210) 225-5437
Sponsored By: ICON Early Phase Services Stipend: $3000 - $3000 Length of Study: 4 weeks Research Facility: In-Patient Gender: Both Age: 18 - 65 Health Condition: Celiac Disease More Information: Vital signs, ECGs, physical examinations, Holter monitoring and pregnancy, drug and alcohol screens will be performed. Blood and urine samples will also be obtained during this study. Please note that fingernail polish and fake nails are not allowed due to oximetry testing.
Participants in Part A will complete: 1 screening visit 3 consecutive overnights 4 outpatient visits 7 phone calls To determine if you fully qualify, it will be necessary to obtain blood samples after a 10-hour fast. You have the option of fasting for the screening appointment, or, you may return at a later date. You may need to provide medical records to participate in this study. For more information, see below.
Qualified participants may be compensated up to $3,000 for time and travel.
If you are able to answer “YES” to the following statements, you may qualify for this study.
I am an adult with diagnosed celiac disease and I have had a biopsy to confirm that I have celiac disease
I am between 18 and 65 years old
My BMI is between > 16 and ≤ 32.0 kg/m2
I have not been exposed to gluten for 2 months prior to enrollment for this study and I agree to maintain a gluten-free diet while on study
I have not had uncontrolled celiac disease and/or complications of celiac disease or celiac symptoms within 8 weeks of screening
I do not smoke or use any tobacco products and I have not used nie products within 6 months of screening. I agree not to smoke for the duration of the study and to abide by the rules of the clinic, which is a non-smoking facility.
I have not received an investigational study drug within 30 days prior to 1st dose
I agree not to participate in another investigational study while participating in this study
If Female, I am not pregnant or breastfeeding and I do not plan to become pregnant before or during the study
If Female and capable of becoming pregnant, I agree to use a medically accepted od of contraception throughout the study and for 30 days after completing the study. These ods include abstinence, a monogamous relationship with a male who has had a vasectomy, use of an IUD, a double-barrier contraceptive od (e.g., condom with spermicide, condom and diaphragm with spermicide, contraceptive implant, injectable contraceptive, or oral contraceptive). Medically accepted ods of contraception for you and/or your partner will be defined in detail at screening.
If Female and not capable of becoming pregnant, I have been postmenopausal for at least 12 months, or, I have been surgically sterile (ovaries removed, tubes tied, uterus removed) for at least 6 months
If Male, I agree to practice a od of medically approved contraception which includes abstinence, a monogamous relationship with a female who is not capable of becoming pregnant, a vasectomy, or the use of condoms throughout the study and for 30 days after receiving the study drug
I have not had any significant changes, nor do I anticipate changes, to prescription or nonprescription medication used to manage an underlying condition within 60 days prior to Day 1
I am not currently taking nor have I received systemic biologics 6 months prior to Day 1
I have not taken, nor am I taking, an immunomodulatory or immune suppressing medical treatment (e.g., azathioprine, otrexate) during the 2 months prior to screening
I am not taking immunosuppressive doses of corticosteroids daily, or on alternative days for 2+ weeks, within 6 months prior to the first dose of study drug
I do not have a history of hypersensitivity (e.g., of anaphylaxis, angioedema, atopic dermatitis, or urticarial) or severe allergic reaction (any reaction that resulted in hospitalization), congenital anomaly, or disability, that requires medical intervention to prevent permanent impairment or damage to any other allergens (including medications, food or environmental)
I do not have any untreated or active gastrointestinal disease (e.g., peptic ulcer disease, esophagitis, irritable bowel syndrome, inflammatory bowel disease, or microscopic colitis)
I have not had an acute illness including fever (> 100.4 degrees), within 28 days of check-in for Day -1
I have not had an active malignancy, history of malignancy or chemotherapy, within the past 5 years (NOTE: other than past history of localized or surgical removal of basal cell skin cancer, cervical cancer in situ treated successfully, or by hysterectomy)
I do not have a history of any drug or alcohol abuse within the past 5 years, or alcohol consumption greater than 21 units per week.A unit of alcohol is equivalent to: 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor.) (NOTE: Alcohol consumption will be prohibited prior to check-in at the clinical research unit on Day 1 and throughout the study.)
I do not have a history or presence of any eating dis
I have not received a live vaccine (within 28 days) prior, or a subunit vaccine (within 14 days) prior to first dosing/Day 1 and I do not plan to have a vaccination during the study
I have not donated blood or plasma ≤ 56 days prior to Screening and I do not plan to donate blood or plasma within 5 weeks of completing the study.
|
|
|
Post by David Grey on Nov 16, 2017 10:52:57 GMT -5
hi Florida Girl - I want to clarify soing with you as I value your input in this website. VCT does NOT make the rules about dual screening. In fact the system is completely informational to the research site. It is the site decision to allow dual screening and MOSTLY ALL DO. VCT helps ensure subjects are NOT dual enrolling or violating the specific study's washout period. Thanks for your participation on this website. In the short time that I have taken over, its become apparent that you bring a lot to this community.
|
|
|
Post by David Grey on Nov 16, 2017 9:11:02 GMT -5
Florida Girl and Puntkicker - we think we fixed private message issue - can you retry and just let me know if successful?
|
|